MX2018008192A - Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmaceuticamente aceptables; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes. - Google Patents
Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmaceuticamente aceptables; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.Info
- Publication number
- MX2018008192A MX2018008192A MX2018008192A MX2018008192A MX2018008192A MX 2018008192 A MX2018008192 A MX 2018008192A MX 2018008192 A MX2018008192 A MX 2018008192A MX 2018008192 A MX2018008192 A MX 2018008192A MX 2018008192 A MX2018008192 A MX 2018008192A
- Authority
- MX
- Mexico
- Prior art keywords
- bacterial
- isoquinolin
- isomers
- resistant
- pharmaceutically acceptable
- Prior art date
Links
- 230000001580 bacterial effect Effects 0.000 title abstract 3
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 4
- 108010059993 Vancomycin Proteins 0.000 abstract 3
- 229960003165 vancomycin Drugs 0.000 abstract 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract 3
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract 2
- BTSOSKQGRVRCAB-UHFFFAOYSA-N 4H-pyrido[3,4-f]quinazoline-1,3-dione Chemical class C1=CN=CC2=C(C(=O)NC(=O)N3)C3=CC=C21 BTSOSKQGRVRCAB-UHFFFAOYSA-N 0.000 abstract 1
- 108010013198 Daptomycin Proteins 0.000 abstract 1
- 241000194033 Enterococcus Species 0.000 abstract 1
- 241000194032 Enterococcus faecalis Species 0.000 abstract 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 1
- 229960005484 daptomycin Drugs 0.000 abstract 1
- 229940032049 enterococcus faecalis Drugs 0.000 abstract 1
- 229960003907 linezolid Drugs 0.000 abstract 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract 1
- 229960003085 meticillin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención provee derivados pirimido-isoquinolin-quinon as de formula I, sus sales, isomeros, tautomeros farmacéuticamente aceptables; composición farmacéutica; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas resistentes, tales como Staphylococcus aureus resistente a la meticilina (MRSA o SARM), Staphylococcus aureus con resistencia intermedia a la vancomicina(VISA), Staphylococcus aureus con resistencia a la vancomicina(VRSA), Enterococcus spp. resistentes a la vancomicina(VRE), Enterococcus faecalis, Staphylococcus aureus emergentes con resistencia a linezolid y/o cepas bacterianas no susceptibles a daptomicina. (ver Fórmula) Donde los radicales R1, R2, R3, R4 y R5, son tal como se definen en la memoria descriptiva de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2015003780A CL2015003780A1 (es) | 2015-12-30 | 2015-12-30 | Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes. |
| PCT/CL2016/050080 WO2017113031A1 (es) | 2015-12-30 | 2016-12-29 | Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticamente aceptables; composición farmacéutica; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008192A true MX2018008192A (es) | 2018-11-09 |
| MX383627B MX383627B (es) | 2025-03-14 |
Family
ID=57234031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008192A MX383627B (es) | 2015-12-30 | 2016-12-29 | Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticamente aceptables; composición farmaceutica; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11390622B2 (es) |
| EP (1) | EP3404026B1 (es) |
| CN (1) | CN109121411B (es) |
| CL (1) | CL2015003780A1 (es) |
| ES (1) | ES2951489T3 (es) |
| MX (1) | MX383627B (es) |
| WO (1) | WO2017113031A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118903076B (zh) * | 2024-07-23 | 2025-07-15 | 佛山市南海区第四人民医院 | 氢醌类衍生物在抑制肺炎克雷伯菌活性及制备抗肺炎克雷伯菌药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102793A2 (en) | 2001-06-19 | 2002-12-27 | Warner-Lambert Company Llc | Quinazolinediones as antibacterial agents |
| DE10341614A1 (de) | 2003-09-10 | 2005-04-28 | Basf Ag | Verfahren zur Herstellung von Xylylendiamin (XDA) |
| BRPI0416708A (pt) | 2003-11-18 | 2007-01-16 | Warner Lambert Co | derivados de aminoquinazolidinadiona antibacterianos |
-
2015
- 2015-12-30 CL CL2015003780A patent/CL2015003780A1/es unknown
-
2016
- 2016-12-29 US US16/067,033 patent/US11390622B2/en active Active
- 2016-12-29 MX MX2018008192A patent/MX383627B/es unknown
- 2016-12-29 ES ES16880235T patent/ES2951489T3/es active Active
- 2016-12-29 WO PCT/CL2016/050080 patent/WO2017113031A1/es not_active Ceased
- 2016-12-29 CN CN201680081761.1A patent/CN109121411B/zh not_active Expired - Fee Related
- 2016-12-29 EP EP16880235.3A patent/EP3404026B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109121411A (zh) | 2019-01-01 |
| EP3404026A1 (en) | 2018-11-21 |
| EP3404026A4 (en) | 2019-11-27 |
| MX383627B (es) | 2025-03-14 |
| EP3404026B1 (en) | 2023-03-15 |
| CL2015003780A1 (es) | 2016-09-16 |
| US20190367505A1 (en) | 2019-12-05 |
| CN109121411B (zh) | 2021-01-08 |
| US11390622B2 (en) | 2022-07-19 |
| ES2951489T3 (es) | 2023-10-23 |
| WO2017113031A1 (es) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| CO2017013709A2 (es) | Lactamas bicíclicas. | |
| MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| MX2016009013A (es) | Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4). | |
| MX2016013052A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| MX385876B (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX361370B (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| CO2017009994A2 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| BR112016024235A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| CO2020003475A2 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| GT201600232A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| MX2018008192A (es) | Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmaceuticamente aceptables; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes. | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |